Incyte sees FY24 Jakafi net product revenue $2.7B-$2.8B

Incyte is maintaining its full year 2024 revenue and expense guidance. Incyte’s guidance is summarized below. Guidance does not include revenue from any potential new product launches or the impact of the acquisition of Escient Pharmaceuticals or any other potential future strategic transactions. Sees Jakafi net product revenues $2,690 – $2,750M…